Abstract
Urate oxidase is considered as an important therapeutic enzyme used to control hyperuricemia. In spite of widespread distribution in numerous (micro)organisms, active urate oxidase is absent in higher primates (humans and apes) due to gene mutations. Considering the therapeutic significance of urate oxidase, further understanding on the inactivation process of the enzyme during primate evolution is critical. This study, therefore, aims to express genetically modified human urate oxidase in the methylotrophic yeast Pichia pastoris. Accordingly, the genetically modified human urate oxidase was successfully expressed intracellularly and extracellularly under the control of an alcohol oxidase promoter and was subjected to the enzyme activity assay. The results demonstrated that reactivating the non-functional human urate oxidase gene fully or even moderately by simply replacing the premature stop codons is impossible. This finding confirms the idea that a number of successive loss-of-function missense mutations occurred during evolution, making higher primates functional uricase-deficit and vulnerable to hyperuricemic disorders.
Keywords: Expression, hominoid evolution, Pichia pastoris, pseudogene, urate oxidase, uricase.
Current Pharmaceutical Biotechnology
Title:Engineering Human Urate Oxidase: Towards Reactivating It as an Important Therapeutic Enzyme
Volume: 17 Issue: 2
Author(s): Fatemeh Dabbagh, Mohammad B. Ghoshoon, Shiva Hemmati, Mozhdeh Zamani, Milad Mohkam and Younes Ghasemi
Affiliation:
Keywords: Expression, hominoid evolution, Pichia pastoris, pseudogene, urate oxidase, uricase.
Abstract: Urate oxidase is considered as an important therapeutic enzyme used to control hyperuricemia. In spite of widespread distribution in numerous (micro)organisms, active urate oxidase is absent in higher primates (humans and apes) due to gene mutations. Considering the therapeutic significance of urate oxidase, further understanding on the inactivation process of the enzyme during primate evolution is critical. This study, therefore, aims to express genetically modified human urate oxidase in the methylotrophic yeast Pichia pastoris. Accordingly, the genetically modified human urate oxidase was successfully expressed intracellularly and extracellularly under the control of an alcohol oxidase promoter and was subjected to the enzyme activity assay. The results demonstrated that reactivating the non-functional human urate oxidase gene fully or even moderately by simply replacing the premature stop codons is impossible. This finding confirms the idea that a number of successive loss-of-function missense mutations occurred during evolution, making higher primates functional uricase-deficit and vulnerable to hyperuricemic disorders.
Export Options
About this article
Cite this article as:
Dabbagh Fatemeh, Ghoshoon B. Mohammad, Hemmati Shiva, Zamani Mozhdeh, Mohkam Milad and Ghasemi Younes, Engineering Human Urate Oxidase: Towards Reactivating It as an Important Therapeutic Enzyme, Current Pharmaceutical Biotechnology 2016; 17 (2) . https://dx.doi.org/10.2174/1389201016666150907113055
DOI https://dx.doi.org/10.2174/1389201016666150907113055 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: At Long Last: A Viable Biomedical Model for Fibromyalgia (Daniel J. Wallace (Editor-in-Chief) ]
Current Rheumatology Reviews Anti-Inflammatory Effects of Plasma Circulating Exosomes Obtained from Normal-Weight and Obese Subjects on Hepatocytes
Endocrine, Metabolic & Immune Disorders - Drug Targets Atherosclerosis is an Inflammatory Disorder After All
Current Topics in Medicinal Chemistry Dynamic Role of Macrophage Sub Types on Development of Atherosclerosis and Potential Use of Herbal Immunomodulators as Imminent Therapeutic Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry Nonbacterial Thrombotic Endocarditis (Marantic Endocarditis) in Cancer Patients
Cardiovascular & Hematological Disorders-Drug Targets <i>Prunella vulgaris</i> L: Critical Pharmacological, Expository Traditional Uses and Extensive Phytochemistry: A Review
Current Drug Discovery Technologies Oligomerization of G Protein-Coupled Receptors: Biochemical and Biophysical Methods
Current Medicinal Chemistry Novel Drugs for the Prevention and Treatment of Acute GVHD
Current Pharmaceutical Design Aggregation of Recombinant Monoclonal Antibodies and Its Role in Potential Immunogenicity
Current Pharmaceutical Biotechnology Prevention and Repair of Circulatory Shock and Cerebral Ischemia/Injury by Various Agents in Experimental Heatstroke
Current Medicinal Chemistry Local Inflammation in Chronic Upper Airway Disease
Current Pharmaceutical Design The Central Role Played by Peptides in the Immune Response and the Design of Peptide-Based Vaccines Against Infectious Diseases and Cancer
Current Drug Targets Knock-Out Mice in Osteoarthritis Research
Current Rheumatology Reviews Drug Delivery Systems Based on Polymeric Micelles and Ultrasound: A Review
Current Pharmaceutical Design Iodine-Refractory Thyroid Carcinoma
Reviews on Recent Clinical Trials Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors
Current Pharmaceutical Design Template Synthesis of Tubular Nanostructures for Loading Biologically Active Molecules
Current Topics in Medicinal Chemistry Hendra and Nipah Viruses: Pathogenesis and Therapeutics
Current Molecular Medicine Targeting Angiogenesis in Head and Neck Cancer
Current Cancer Drug Targets Pharmacological Control of Autophagy: Therapeutic Perspectives in Inflammatory Bowel Disease and Colorectal Cancer
Current Pharmaceutical Design